Apple Inc. shares traded 0.62% lower at $340.83 as investors await fiscal fourth-quarter results on November 2, with the iPhone Duo launching October 23.

The company announced expanded U.S. manufacturing partnerships under its American Manufacturing Program. Perryman will supply grade 5 titanium for the iPhone Duo enclosure, with Apple committing up to $100 million over three years. Qnity Electronics will produce advanced films for the iPhone 18 Pro camera. Nearly 100 components in both phones are made by U.S. companies, including Broadcom’s radio frequency chips and Corning’s cover glass. TSMC’s Arizona fab will produce more than 100 million chips for Apple in 2026. This aligns with Apple’s $600 billion four-year U.S. commitment.

iPhone Duo sells out, iPhone 18 Pro orders cut

Pre-orders for the iPhone Duo sold out within moments on October 16. Shipping dates slipped to November 16 and then November 23. Nikkei Asia reported Apple told suppliers to cut October component orders for the iPhone 18 Pro and Pro Max by 15% to 20%. JPMorgan analyst Samik Chatterjee raised his price target to $360 from $340, maintaining an Overweight rating. He stated the cuts reflect a new launch cadence rather than a weaker cycle.

Fiscal fourth-quarter outlook

Analysts estimate earnings per share of $1.98 on revenue of $113.07 billion. Apple guided to revenue growth of 9% to 11% and a gross margin of 47% to 48%. The quarter ended September 26 and includes only the first nine days of iPhone 18 Pro sales. The iPhone Duo will not appear in this quarter’s results.

What the numbers show

The divergence between the iPhone Duo’s immediate sellout and the 15-20% component order cuts for the iPhone 18 Pro suggests a strategic inventory management shift rather than demand weakness. With the Duo excluded from Q4 results, the quarter’s revenue relies heavily on the initial nine days of 18 Pro sales against a backdrop of guided mid-teens iPhone growth.

Apple Inc received a downgrade from Loop Capital on Tuesday, shifting from Buy to Hold with a reduced price target of $330. This move aligns with broader analyst caution affecting healthcare and transportation stocks.

Apple price target slashed

Loop Capital analyst Ananda Baruah lowered the price target for Apple to $330 from $370. The downgrade reflects a shift in outlook for the technology giant. Apple shares closed at $342.94 on Monday, trading above the new target price.

Healthcare sector adjustments

Jefferies analyst Keith Devas issued downgrades for two major animal health companies. Zoetis Inc was moved from Buy to Hold, with its price target cut to $83 from $103. Zoetis closed at $79.59 on Monday. Similarly, Elanco Animal Health Inc saw its rating drop to Hold from Buy. Its price target was reduced to $24 from $31, following a closing price of $23.49.

Transportation ratings revised

Baird analyst Daniel Moore downgraded Werner Enterprises Inc to Neutral from Outperform. The price target for Werner was cut to $32 from $43. The stock closed at $30.22. In the same sector, Baird’s Dan Moore downgraded Heartland Express Inc to Neutral from Outperform. The price target fell to $12 from $16, while the stock closed at $10.53.

Summary of analyst actions

What the numbers show

The data reveals a divergence in valuation risk between the technology and animal health sectors. For Apple, the new price target of $330 is approximately 3.8% below Monday's closing price of $342.94, suggesting limited immediate upside according to this specific analyst view. In contrast, the new targets for Zoetis ($83 vs $79.59 close) and Elanco ($24 vs $23.49 close) remain slightly above current trading levels, indicating that despite the rating downgrades, these analysts still see modest potential for recovery or stability compared to the tech giant.